SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc., a hepatitis B virus ("HBV") drug developer, announced today the appointment of Michael Kamdar as President.
Mr. Kamdar has more than 25 years of fundraising, management, business development and commercial experience in the biotechnology, pharmaceutical and diagnostic industries. He has held executive positions at both public and private companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals and Genoa Pharmaceuticals, representing some of the most successful in the pharmaceutical and biotechnology communities. Over the course of his career to-date, Mr. Kamdar has accounted for deal transactions in excess of $1 billion and has raised in excess of $300 million from venture capital and public capital market sources. Mr. Kamdar currently serves as a member of the Board of Directors of Genoa Pharmaceuticals and Cellana, LLC.
Dr. Robert Foster, Ciclofilin's CEO stated, "We are delighted to welcome Michael to our company as President. He is a seasoned professional with many years of senior pharmaceutical and biotech executive management experience. Michael is well known in the industry and has been previously involved in the development and commercialization of antiviral drugs."
Mr. Kamdar said, "Ciclofilin is developing a novel medication for the treatment of chronic HBV infection. HBV affects a great number of people and can have serious health consequences, including liver cancer and death. I am very pleased to be joining the executive team at Ciclofilin, as they have many decades experience in drug development, and are well suited to meet the challenge of HBV treatment head on."
Ciclofilin is a life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company's lead drug, CPI-431-32, is uniquely designed to specifically target the host and not the virus. By targeting the host, CPI-431-32 interferes with the necessary cellular components that allow HBV to persist in the liver and cause disease. CPI-431-32 blocks HBV at multiple stages of the viral life cycle, including virus entry and replication, and also stimulates the immune system to attack the virus. CPI-431-32 may also reduce liver disease through additional mechanisms independent of the antiviral activities (liver inflammation and fibrosis, liver cirrhosis, and hepatocellular carcinoma).
This press release contains forward-looking statements, including with respect to the potential of our lead drug CPI-431-32 for the treatment of HBV. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the significance of our preclinical results and potential applications of our compound for the treatment of HBV patients. Statements that are not historical facts are based on our management's current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. These statements speak only as of the date of this release, and are subject to a number of risks, uncertainties and assumptions. Ciclofilin undertakes no obligation to update or revise these statements, except as required by applicable law.
CONTACT: Investor Contact Ciclofilin Pharmaceuticals, Inc., Dr. Robert T. Foster, CEO, +1 (780) 909-5041; Email: [email protected] Mr. Michael Kamdar, President, +1 (858) 733-1308; Email: [email protected] Media Contact Steve Kilmer, +1 (647) 872-4849; Email: [email protected]